Skip to main content

Table 1 Baseline characteristics of LYM3001 patients with high-risk FL (ITT population)

From: Bortezomib plus rituximab versus rituximab in patients with high-risk, relapsed, rituximab-naïve or rituximab-sensitive follicular lymphoma: subgroup analysis of a randomized phase 3 trial

 

Bortezomib-rituximab (N=103)

Rituximab (N=98)

Median age, years (range)

61 (38–83)

60 (21–84)

Aged >65 years, n (%)

31 (30)

25 (26)

Male, n (%)

53 (51)

42 (43)

Race, n (%)

  

White

78 (76)

65 (66)

Asian

20 (19)

29 (30)

Other

5 (5)

4 (4)

Region, n (%)

  

USA and Canada

8 (8)

10 (10)

European Union

34 (33)

28 (29)

Rest of the World*

61 (59)

60 (61)

ECOG performance status, n (%)

  

0

36 (35)

35 (36)

1

56 (54)

52 (53)

2

11 (11)

11 (11)

Ann Arbor Stage, n (%)

  

II

0

1 (1)

III

36 (35)

45 (46)

IV

67 (65)

52 (53)

High tumor burden by modified GELF criteria[12], n (%)

103 (100)

98 (100)

High (≥3) FLIPI score[7], n (%)

103 (100)

98 (100)

Elevated serum LDH, n (%)

70 (68)

61 (62)

Median time from initial diagnosis, months (range)

35.8 (2–233)

38.5 (1–197)

Number of prior lines of therapy, n (%)

  

1

43 (42)

35 (36)

2

25 (24)

31 (32)

≥3

35 (34)

32 (32)

Common prior therapies, n (%)

  

CHOP

41 (40)

40 (41)

CVP

35 (34)

23 (23)

Single-agent rituximab

17 (17)

13 (13)

Chlorambucil-prednisone

9 (9)

14 (14)

R-CHOP

10 (10)

12 (12)

R-CVP

9 (9)

12 (12)

Single-agent chlorambucil

10 (10)

10 (10)

Any prior rituximab therapy, n (%)

40 (39)

40 (41)

>1 year since last FL treatment, n (%)

53 (51)

48 (49)

Creatinine clearance >30–60 mL/min, n (%)

18 (17)

24 (24)

  1. *Including 21%/12% from Russia, 10%/14% from People’s Republic of China, 9%/14% from India, and 9%/11% from Brazil in the bortezomib-rituximab/rituximab arms.
  2. ECOG, Eastern Cooperative Oncology Group; GELF, Groupe d’Etude des Lymphomas Folliculaires; FLIPI, Follicular Lymphoma International Prognostic Index; LDH, lactate dehydrogenase.